Labcorp's PGDx elio® tissue complete CDx has received FDA approval as a companion diagnostic to identify advanced melanoma patients with specific BRAF mutations. This test helps clinicians determine which patients may benefit from targeted BRAF and BRAF/MEK inhibitor therapies, improving treatment options for a deadly skin cancer with low survival rates. The test is scalable for use in hospitals and labs, supporting broader access to personalized cancer care. Labcorp continues to expand its precision medicine portfolio with this approval, enhancing patient access to advanced molecular diagnostics.
Evernorth has agreed to issue $30 million in 4% convertible notes due 2031 to finance XRP purchases and ecosystem activities, contingent on its merger with Armada Acquisition Corp. II closing in Q4 2026. The proceeds will support Evernorth's strategy...
NEAR crypto token jumped 24.52%, driven by increased trading activity, whale orders, and expanded AI utilities including staking credits for 43 AI models. Its confidential TVL surpassed $70 million, triggering milestone token incentives locked until ...
Cloud3 Ventures has hired a specialized consulting team to help identify and evaluate potential investment and acquisition opportunities in the space, defence, and deep technology sectors. The company aims to focus on businesses with unique technolog...
Kahn Swick & Foti, LLC has started an investigation into PayPal following the company's disappointing 2025 financial results and the unexpected departure of its CEO. PayPal had previously given positive forecasts about growth in its Branded Checkout ...
With just two weeks left in Q2 2026 reporting and about four weeks before Q3 earnings begin, S&P 500 earnings per share (EPS) estimates have grown remarkably, rising 50% in 18 months to an expected $363.71 by year-end 2026. This surge is largely due ...
